Unichem Pharmaceuticals (USA), Inc. received the long-awaited FDA approval Monday for its ANDA 207428, providing generic access to oral Sotalol Hydrochloride. This move positions Unicem to capitalize on market opportunities within the established class of antiarrhythmics, regardless of the original brand's patent status.